Short Interest in Conexeu Sciences Inc. (NASDAQ:CNXU) Grows By 357.1%

Conexeu Sciences Inc. (NASDAQ:CNXU) was the recipient of a significant increase in short interest in July. As of July 15th, there was short interest totaling 170,673 shares, an increase of 357.1% from the June 30th total of 37,335 shares. Based on an average trading volume of 156,558 shares, the days-to-cover ratio is presently 1.1 days. Approximately 0.6% of the company’s stock are short sold.

Analysts Set New Price Targets

CNXU has been the subject of a number of research reports. Wall Street Zen raised Conexeu Sciences to a “hold” rating in a report on Saturday, May 30th. HC Wainwright initiated coverage on Conexeu Sciences in a research note on Monday, June 22nd. They issued a “buy” rating and a $20.00 target price for the company. Finally, Zacks Research upgraded Conexeu Sciences to a “hold” rating in a report on Monday, June 29th. One research analyst has rated the stock with a Buy rating and one has issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $20.00.

Conexeu Sciences Stock Performance

Shares of Conexeu Sciences stock opened at $8.57 on Friday. The firm has a fifty day moving average of $11.71. Conexeu Sciences has a 12-month low of $8.14 and a 12-month high of $18.79. The firm has a market cap of $229.32 million and a PE ratio of -77.91.

Conexeu Sciences (NASDAQ:CNXU) last announced its earnings results on Monday, June 15th. The company reported ($0.11) earnings per share (EPS) for the quarter.

Insider Activity at Conexeu Sciences

In related news, Director Lynn Sebastian Purcell acquired 202,500 shares of the firm’s stock in a transaction that occurred on Thursday, June 18th. The stock was purchased at an average cost of $0.80 per share, with a total value of $162,000.00. Following the transaction, the director directly owned 2,734,240 shares of the company’s stock, valued at $2,187,392. This trade represents a 8.00% increase in their position. The purchase was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.

About Conexeu Sciences

Conexeu is a company focused on building a new class of collagen-based regenerative tissue products. The Company was incorporated on November 2, 2022 under the Business Corporations Act (British Columbia) and was continued out of British Columbia and domesticated into the State of Nevada under the laws of the State of Nevada on April 10, 2025. — Conexeu is an early-stage medical device company formed to acquire and commercialize intellectual property (“IP”) developed over more than a decade at the University of British Columbia (the “University”) and the BC Professional Firefighters Burn and Wound Healing Laboratory.